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using data on the risk of pneumococcal disease, the serotype-
adjusted vaccine efﬁcacy, the vaccine price, decrease in the fre-
quency of adverse outcomes and quality of life for patients with
sequelae from pneumococcal disease. Due to uncertainty with
respect to herd immunity, results are presented both with and
without potential effects of herd immunity. RESULTS: Disre-
garding indirect costs, the incremental cost per QALY using 4
Prevenar doses was €96000 when herd immunity was included
and €140,000 when it was not (€57,000 and €83,000 if 3 doses
offer the same effectiveness as 4). Also accounting for indirect
costs, the numbers with 4 doses would be €37,000 and €56,000,
respectively. With the most optimistic assumptions, vaccination
would be cost saving. The vaccine price and efﬁcacy, and otitis
incidence were crucial factors in sensitivity analyses. Monte
Carlo simulations indicate that the results were robust to uncer-
tainty in other parameters. CONCLUSION: The cost-effective-
ness of pneumococcal vaccination will in particular depend on
the price of the vaccine, the efﬁcacy of the vaccine, the efﬁcacy
of three versus four vaccine shots, and the extent of herd immu-
nity. In Norway, €62,500 per QALY is the ofﬁcial cost-effec-
tiveness threshold. Vaccination can therefore be considered
cost-effective. In November 2005 the Norwegian Government
included Prevenar in the public vaccination program.
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OBJECTIVE: Invasive mycoses are associated with high mortal-
ity, therefore consuming important health care resources. Cost-
effectiveness of voriconazole vs. amphotericin B deoxycholate
(CAB) for the primary treatment of invasive aspergillosis (IA)
was evaluated using data from a randomized comparative trial
(Herbrecht, NEJM 2002), that showed the superiority of
voriconazole in terms of clinical response, survival and safety
when used as primary therapy for IA. METHODS: A model for
analytical decision was designed based on the information pro-
vided by this clinical study. Changes in the antifungal treatment
due to lack of response, as well as renal or hepatic toxicity with
the initial treatment were assessed, considering direct medical
costs only, reported in Argentine pesos. RESULTS: Average total
treatment cost in the voriconazole arm was $44,040 vs. $45,428
in the CAB arm. Using the model assumptions (efﬁcacy: 52.8%
for voriconazole, 31.6% for CAB) voriconazole was the domi-
nant treatment vs. CAB as primary therapy, with a cost per 
successfully treated patient of $83,444.96 vs. $143,858.26
respectively. One-way sensitivity analysis was performed in order
to assess the impact of relevant key variables (cost of antifun-
gals, cost of hospitalization, etc.) Even after changing these vari-
ables in a wide range, voriconazole was still cost-saving.
CONCLUSIONS: Incremental cost-effectiveness analysis indi-
cated that voriconazole was the dominant therapy due to both
lower costs and higher efﬁcacy.
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OBJECTIVES: Linezolid, the ﬁrst available oxazolidinone, has
shown efﬁcacy in the treatment of methicillin-resistant Staphy-
lococcus aureus (MRSA) infections, including nosocomial pneu-
monia. In patients with MRSA nosocomial pneumonia, survival
rate was higher for those treated with linezolid than patients
treated with vancomycin (80% versus 63.5%). Moreover, clini-
cal cure rate was superior for linezolid (59% vs 35.5%) (Chest
2003;124:1789–97). We analyzed the economic impact of these
clinical outcomes in an Argentinean setting using a decision-
analytic model. METHODS: A decision-analytic model was
developed to estimate the costs and consequences of using line-
zolid versus vancomycin in hospitalized patients with nosoco-
mial pneumonia in an Argentinean setting. Clinical and other
parameters were taken from published trials. Three Argentinean
infectologists provided data on resource utilization. For costing
purposes (tests, hospitalization, adverse events and drugs) ALFA-
BETA and IECS unit costs database were used (both are pub-
lished). Outcomes consisted of total costs per patient, cost per
death avoided, cost per life-year gained, and cost per cure.
RESULTS: According to the model results, an additional 14.3%
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of patients treated with linezolid versus vancomycin were cured
(69.6% versus 55.4%). Average total treatment cost was
$14,268 for linezolid-treated patients versus $13,065 for van-
comycin-treated patients, with an incremental ratio of $8429 per
additional patient cured. Death rates were 20.4% for linezolid
versus 35% for vancomycin, with an average 2.49 life-years
gained per linezolid patient in a 65-year-old cohort (13.7 versus
11.2 years). The incremental cost per death avoided and per life
year gained were $7299 and $482, respectively. To evaluate the
robustness of ﬁndings sensitivity analyses were carried out mod-
ifying the value of several key variables. As a result of changing
them suitably, the overall conclusions remained the same. CON-
CLUSION: From the Argentinean perspective, linezolid is cost-
effective versus vancomycin in the treatment of nosocomial
pneumonia due to suspected MRSA.
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OBJECTIVES: Ventilator—associated pneumonia (VAP)
remains a signiﬁcant cause of morbidity and mortality in
Mexico. Development of VAP increases both the duration of
intensive care unit (ICU) stay and hospitalization. The purpose
of this study was to compare the cost—effectiveness ratios
between four antimicrobial treatments for hospitalized adult
patients with suspected or proven Gram-positive VAP due to
Staphylococcus aureus in two ICUs of the Social Security
Mexican Institute. METHODS: A decision tree model was devel-
oped using a Bayesian approach. The model simulated treatment
of a hypothetical cohort of 1000 patients diagnosed with VAP
during a time horizon of 12 weeks. Patients initiate treatment
with one of four antimicrobial agents; linezolid, vancomycin,
teicoplanin and imipenem. Conditional probabilities of the
model were obtained from published clinical trials. Effectiveness
measure was the clinical cure rate for patients with suspected or
proven Staphylococcus aureus VAP. The analysis was conducted
from the healthcare payer’s perspective (only direct medical costs
were used). Resource use and costs were obtained from hospital
records and Mexican ofﬁcial databases. Probabilistic sensitivity
analysis was performed and acceptability and health net beneﬁts
curves were constructed. RESULTS: Linezolid was associated
with a shorter ICU stay and a higher clinical cure in comparison
with vancomicyn, teicoplanin and imipenem (p < 0.005). Line-
zolid showed on the 12-weeks period the lowest expected
average costs per patient treated (US$38,182.9) followed by van-
comicyn (US$39,345.5) and imipenem (US$42,235). Linezolid
also showed the highest clinical cure rate (57.4%) followed by
vancomcyin (37.2%) and teicoplanin (32.1%). Results were
robust to Monte Carlo ﬁrst order sensitivity analysis. CON-
CLUSIONS: Despite its higher cost in the Mexican market, line-
zolid was cost—effective for treatment of VAP. These results
should be taken into account by Mexican decision makers and
clinicians in the management of patients with suspected or
proven Gram-positive VAP due to Staphylococcus aureus.
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OBJECTIVES: The non-peptidic protease inhibitor (PI)
tipranavir boosted with ritonavir (TPV/r) has shown superior
efﬁcacy compared to investigator selected ritonavir-boosted com-
parator PI (CPI/r) in treatment experienced HIV 1 infected
patients in the RESIST 1 and 2 clinical trials. TPV/r or CPI/r were
administered with an optimized background regimen (OBR). In
addition to the clinical efﬁcacy of TPV/r, healthcare decision-
makers will be interested in the cost-effectiveness of TPV/r.
METHODS: A previously published 3-stage Markov model 
was modiﬁed to reﬂect US practice patterns for treatment-
experienced HIV patients using 2005 costs and combined 48-
week RESIST 1 and 2 trial data. The 12 model health states (HS)
were deﬁned by patients’ CD4+ count and viral load, with cost
and risk of AIDS deﬁning events (ADEs) being linked to each
HS. Cycle length was three months and transition through the
model continued until 90% of patients had died. Disease pro-
gression beyond the 48-week trial data was based on HAART
treatment experienced patients from the Medical University of
South Carolina database. Costs were estimated from the payer
perspective, including AWP drug prices and costs for patient
monitoring and ADEs from SC Medicaid patients. RESULTS:
TPV/r patients remained longer in HS deﬁned by higher CD4+
count and lower viral load compared to CPI/r patients. This
reduced the rate of ADEs (12.35% over 5 years) and resulted in
9.6 quality-adjusted life-months gained over the model time
horizon. The incremental cost-effectiveness ratio (ICER) of
TPV/r vs. CPI/r was $56,668 per QALY (discounted at 3%). Sub-
group analysis of patients not treated with enfuvirtide as part of
their OBR reduced the ICER to $49,467 per QALY. CONCLU-
SIONS: The ICER for TPV/r falls well within the $/QALY range
of $50,000–$100,000 considered acceptable. Treating patients
with TPV/r in earlier treatment regimes, not requiring augmen-
tation with enfuvirtide, yielded an ICER below $50,000 per
QALY.
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OBJECTIVES: Nosocomial pneumonia (NP) is costly in terms
of resource utilization and mortality. Patients with ventilator-
associated pneumonia (VAP) have a higher risk of death than
those with NP from other sources. The differences in risk and
costs are attributable in part, to differences in the underlying
pathogens. The purpose of this study is to characterize the out-
comes and costs associated with NP, speciﬁcally examining 
the impact of mechanical ventilation. METHODS: We used
Premier’s 2003 hospital dataset for this study. These data origi-
nate from 1500 hospitals in the United States. Records with a
non-missing admission code and a diagnosis of pneumonia some-
time during the stay were retained. To restrict the sample to those
with NP, records with a diagnosis of pneumonia at admission as
well as those with an antibiotic on day one were deleted. CPT-
codes were used to identify mechanical ventilation and text
strings were searched to identify antibiotic therapy. Length of
stay and costs were calculated by ward type. RESULTS: The ﬁnal
